卢峰，博士，讲师，1990年生，本科、硕士毕业于鲁东大学和福州大学。2021年6月博士毕业于暨南大学肿瘤分子生物学教育部重点实验室。2021年加入徐州医科大学肿瘤生物治疗研究所。目前从事肿瘤代谢相关蛋白修饰对于肾癌发生及转移的作用及机制研究，先后在包括Journal of Thoracic Oncology、Theranostics、Molecules、Cell Cycle等刊物发表SCI论文4篇。

PUBLICATIONS

1.Lu F*,Zhou Q*, Liu L*, Zeng GD, Ci WM, Liu WT, et al. A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients.(2020)Theranostics,10:484-497.

2.Fang WF*, Gan JD*, Hong SD*,Lu F*,Zhang L.MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.(2019)Journal of Thoracic Oncology,14 :E148-E151.

3.Li B*, Liang JX*,Lu F*,Zeng GD, Zhang JD, Ma YX, et al. Discovery of Novel Inhibitor for WNT/beta-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.(2020)Molecules,25.

4.Liang JX*,Lu F*,Li B*, Liu L, Zeng GD, Zhou Q, et al. IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function.(2019)Cell Cycle,18:3300-3312.